The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials

Abstract

ObjectiveThis systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to determine the effect of alpha-lipoic acid (ALA) supplementation on the inflammatory markers among patients with metabolic syndrome (MetS) and related disorders.MethodsWe searched the following databases until November 2017: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran’s Q test and I-square (I2) statistic. Data were pooled by using the random-effect model and standardized mean difference (SMD) was considered as the summary effect size.ResultsEighteen trials out of 912 potential citations were found to be eligible for our meta-analysis. The findings indicated that ALA supplementation significantly decreased C-reactive protein (CRP) (SMD = − 1.52; 95% CI, − 2.25, − 0.80; P < 0.001), interlokin-6 (IL-6) (SMD = − 1.96; 95% CI, − 2.60, − 1.32; P < 0.001), and tumor necrosis factor alpha levels (TNF-α) (SMD = − 2.62; 95% CI, − 3.70, − 1.55; P < 0.001) in patients diagnosed with metabolic diseases.ConclusionIn summary, the current meta-analysis demonstrated the promising impact of ALA administration on decreasing inflammatory markers such as CRP, IL-6 and TNF-α among patients with MetS and related disorders.Electronic supplementary materialThe online version of this article (10.1186/s12986-018-0274-y) contains supplementary material, which is available to authorized users.

Impact of Alpha-Lipoic Acid Chronic Discontinuous Treatment in Cardiometabolic Disorders and Oxidative Stress Induced by Fructose Intake in Rats

“…Due to its ability to reduce OS and serum uric acid level, to improve general antioxidant capacity by increasing GSH level and GPx activity or to down-regulate NF-kB [42,63] and upregulate heme-oxygenase-1 expressions [41], the AL discontinuous treatment ameliorates the elevation of serum CRP, thus preventing the systemic inflammatory process induced by chronic fructose consumption. Even if there are studies that support a decrease in inflammatory markers under a treatment with AL in humans, the available data in this context of inflammation are quite controversial, probably due to the different characteristics of population and the variety of studies design [64,65].…”

<p>Effects of Alpha-Lipoic Acid Supplementation on Cardiovascular Disease Risk Factors in β-Thalassemia Major Patients: A Clinical Trial Crossover Study</p>

“…In a systematic review and meta-analysis of RCTs, findings showed that ALA supplementation decreased TNF-α, C-reactive protein (CRP), and interleukin-6 (IL-6) among patients with metabolic syndrome. 12 In a study on obese people, a significant reduction in CRP and TNF-α concentrations was observed following ALA supplementation. 18 In another study, ALA supplementation decreased TNF-α and IL-6 and increased adiponectin levels in obese subjects with impaired glucose tolerance.…”

“…11 Also, studies have shown that this antioxidant has beneficial effects in reducing serum lipids, inflammatory factors, oxidative stress, and CVD risk factors including HCY, OPG and Lp-PLA 2 . [12][13][14] We examined the effect of ALA supplementation on traditional CVD risk factors including cholesterol, HDL-C, LDL-C, triglyceride, etc. in another study that is currently under review.…”

Нові Можливості Застосування Альфа-Ліпоєвої Кислоти: Роль Енантіомерів

“…Спектр клинического применения АЛК очень широк. Препараты АЛК приобрели большую популярность среди эндокринологов при лечении диабетической периферической вегетативной полинейропатии, а также проявлений метаболического синдрома [5]. В неврологии антиоксидантный эффект АЛК особенно важен для лечения ишемической патологии головного мозга (транзиторные ишемические атаки, ишемический инсульт), а также рассеянного склероза, для торможения прогрессирования болезни Альцгеймера [6,7].…”